Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

Background: Despite strong evidence of benefit, uptake of newer glucose-lowering medications that reduce cardiovascular risk has been low. We sought to examine global trends and predictors of use of SGLT2i and GLP-1 RA in patients with type 2 diabetes. Methods: DISCOVER is a global, prospective, obs...

Full description

Bibliographic Details
Main Authors: Arnold, S.V (Author), Chen, H. (Author), Cooper, A. (Author), Gomes, M.B (Author), Khunti, K. (Author), Kosiborod, M. (Author), Rathmann, W. (Author), Shimomura, I. (Author), Tang, F. (Author), Vora, J. (Author), Watada, H. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Cardiovascular disease
Diabetes
Quality of care
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items